From Financial Times: Pharma has interest in obesity (this was predicted after fen/phen litigation)

http://www.ft.com/intl/cms/s/2/90999222-ebc5-11e1-985a-00144feab49a.html#axzz24E30PWMp

Pharma continues to explore novel diabetes investments, slimmer interest in obesity

By Ashley Armstrong in London, and Christine Livoti, Olga Oksman and Kimberly Ha in New York

"The notorious health scare that Wyeth’s (now Pfizer’s [PFE US]) weight-loss pill Pondimin/Redux (known as fen/phen) caused, involving rare cardiac problems, has left a bad aftertaste for big pharma. Wyeth was left with a USD 21bn compensation bill."

High quality global journalism requires investment. Please share this article with others using the link below, do not cut & paste the article. See our Ts&Cs and Copyright Policy for more detail. Email ftsales.support@ft.com to buy additional rights. http://www.ft.com/cms/s/2/90999222-ebc5-11e1-985a-00144feab49a.html#ixzz24E3Gbru7